Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?
11:50am, Thursday, 24'th Jul 2025
BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
11:09am, Thursday, 24'th Jul 2025
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025)
08:04pm, Wednesday, 23'rd Jul 2025
Shares of Pfizer (NYSE: PFE) surged 8.24% over the past month, reducing the stock’s year-to-date loss to 5.02%. Over the past year, PFE has fallen by 8.75%. Recently, the FDA announced it will o
The 5%+ Dividend Stocks I Love Today
07:34pm, Wednesday, 23'rd Jul 2025
Key Points Altria (NYSE: MO) and Bristol Myers Squibb (NYSE: BMY) are highlighted as strong dividend plays yielding over 7% and 5% respectively, offering income stability even amid moderate price unde
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
11:55am, Wednesday, 23'rd Jul 2025
Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.
Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know
06:46pm, Tuesday, 22'nd Jul 2025
Bristol Myers Squibb (BMY) closed at $48.02 in the latest trading session, marking a +2.85% move from the prior day.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FDA--BMS's Supplemental New Drug Application for Sotyktu for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review.
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
02:46pm, Friday, 18'th Jul 2025
Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on high
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Friday, 18'th Jul 2025
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Bristol Myers' drug fails to meet main goal of late-stage anemia trial
07:16am, Friday, 18'th Jul 2025
Bristol Myers Squibb said on Friday its drug Reblozyl in combination with another therapy failed to meet the main goal of a late-stage trial to treat anemia due to a rare bone marrow cancer.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Anemia--BMS Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl in Adult Patients with Myelofibrosis-Associated Anemia.
Boomers Get a Big Beautiful Tax Break: 4 Safe Stocks Yielding 5% to Buy Now
06:43am, Friday, 18'th Jul 2025
President Trump recently signed the “Big, Beautiful” bill, which introduces a temporary “senior bonus” deduction of up to $6,000 for individuals aged 65 and older ($12,000 for married couples
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
11:47am, Thursday, 17'th Jul 2025
Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass tra
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients
07:21am, Thursday, 17'th Jul 2025
US drugmakers Bristol Myers and Pfizer said on Thursday that they will make their blood thinner, Eliquis, available directly to cash-paying patients at discounted rate through a new program.
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
06:59am, Thursday, 17'th Jul 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option.
